A systematic review and meta-analysis recently published in Neurology , the American Academy of Neurology’s medical journal, compared the effectiveness of two clot-dissolving medications doctors use to treat ischemic stroke: tenecteplase and alteplase .
Taking action to dissolve clots can be part of ischemic stroke treatment.
From all the trials, researchers were able to examine data from 3,788 participants who received tenecteplase, and 3,757 participants who received alteplase.
These participants had similar baseline characteristics, stroke symptoms, and time of treatment intervention.
Based on their analyses, participants who received tenecteplase were more likely to experience an excellent functional outcome compared to participants who received alteplase.

Stroke: Which clot-dissolving drug leads to the best outcomes?